U.S. prosecutors are pursuing possible penalties of nearly $13 billion to resolve investigations of OxyContin maker Purdue Pharma after uncovering evidence of criminal and civil misconduct stemming from the company’s alleged role in fueling the nation’s opioid crisis, people familiar with the matter said.
Insights into former president Richard Sackler’s control of Purdue Pharma and his aggressive stance on marketing OxyContin were revealed when internal company documents were unsealed following a four-year court battle in Kentucky.
A recent report from the Associated Press alleges the Sackler family is using similar marketing tactics to push sales of OxyContin in China through another company they own, Mundipharma.
Purdue Pharma LP and the company’s Sackler family owners will be shielded until April 8, 2020, from sprawling opioid litigation to give the maker of OxyContin time to try to reach a legal settlement the drug manufacturer says is worth $10 billion.
Purdue Pharma LP fraudulently transferred funds to members of the wealthy Sackler family who control the OxyContin maker despite knowing the company faced major liabilities that had made it already insolvent, New York’s attorney general alleged.
OxyContin maker Purdue Pharma LP is exploring filing for bankruptcy to address potentially significant liabilities from roughly 2,000 lawsuits alleging the drug manufacturer contributed to the deadly opioid crisis sweeping the United States, people familiar with the matter said.
Acetaminophen, ibuprofen and other nonsteroidal anti-inflammatory drugs (NSAIDs) are better than opioids at easing the intensity of chronic pain in the back, knees or hips, a U.S. experiment suggests.
Montana sued OxyContin maker Purdue Pharma LP, withdrawing from a multistate investigation by attorneys general into opioid manufacturers’ marketing practices and joining a growing list of states that have broken off to pursue individual lawsuits.
Amid a growing U.S. opioid addiction, health insurer Cigna Corp. will stop covering OxyContin – the opioid painkiller sold by Purdue Pharma LP – as of Jan. 1, 2018, and will instead cover an equivalent with a formulation less vulnerable to abuse.